LU92602I2 - Trametinib, optionnellement sous la forme d'un sel, hydrate ou solvate pharmaceutiquement acceptablede celui-ci - Google Patents

Trametinib, optionnellement sous la forme d'un sel, hydrate ou solvate pharmaceutiquement acceptablede celui-ci Download PDF

Info

Publication number
LU92602I2
LU92602I2 LU92602C LU92602C LU92602I2 LU 92602 I2 LU92602 I2 LU 92602I2 LU 92602 C LU92602 C LU 92602C LU 92602 C LU92602 C LU 92602C LU 92602 I2 LU92602 I2 LU 92602I2
Authority
LU
Luxembourg
Prior art keywords
agent
pharmaceutically acceptable
acceptable salt
antitumor
trametinib
Prior art date
Application number
LU92602C
Other languages
English (en)
French (fr)
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of LU92602I2 publication Critical patent/LU92602I2/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Addiction (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
LU92602C 2004-06-11 2014-11-19 Trametinib, optionnellement sous la forme d'un sel, hydrate ou solvate pharmaceutiquement acceptablede celui-ci LU92602I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2004174770 2004-06-11
JP2004327111 2004-11-10
PCT/JP2005/011082 WO2005121142A1 (en) 2004-06-11 2005-06-10 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2h-pyrido’2,3-d! pyrimidine derivatives and related compounds for the treatment of cancer

Publications (1)

Publication Number Publication Date
LU92602I2 true LU92602I2 (fr) 2015-10-27

Family

ID=34970318

Family Applications (1)

Application Number Title Priority Date Filing Date
LU92602C LU92602I2 (fr) 2004-06-11 2014-11-19 Trametinib, optionnellement sous la forme d'un sel, hydrate ou solvate pharmaceutiquement acceptablede celui-ci

Country Status (27)

Country Link
EP (3) EP1761528B1 (da)
JP (3) JP4163738B2 (da)
KR (1) KR100883289B1 (da)
CN (2) CN101006086B (da)
AT (1) ATE383360T1 (da)
AU (1) AU2005252110B2 (da)
BR (1) BRPI0511967B8 (da)
CA (2) CA2569850C (da)
CY (3) CY1107253T1 (da)
DE (1) DE602005004286T2 (da)
DK (2) DK2298768T3 (da)
ES (2) ES2397825T3 (da)
FR (1) FR14C0083I2 (da)
HR (2) HRP20080018T3 (da)
IL (1) IL179671A0 (da)
LU (1) LU92602I2 (da)
ME (1) ME01480B (da)
MX (1) MXPA06014478A (da)
NL (1) NL300701I2 (da)
NO (2) NO338355B1 (da)
NZ (1) NZ552090A (da)
PL (2) PL2298768T3 (da)
PT (2) PT1761528E (da)
RS (2) RS50569B (da)
RU (1) RU2364596C2 (da)
SI (2) SI2298768T1 (da)
WO (1) WO2005121142A1 (da)

Families Citing this family (188)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8101799B2 (en) 2005-07-21 2012-01-24 Ardea Biosciences Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
ES2481402T3 (es) * 2005-07-21 2014-07-30 Ardea Biosciences, Inc. Inhibidores de N-(arilamino)sulfonamida de MEK
US7919598B2 (en) * 2006-06-28 2011-04-05 Bristol-Myers Squibb Company Crystal structures of SGLT2 inhibitors and processes for preparing same
JO2985B1 (ar) 2006-12-20 2016-09-05 Takeda Pharmaceuticals Co مثبطات كينازmapk/erk
ES2320955B1 (es) 2007-03-02 2010-03-16 Laboratorios Almirall S.A. Nuevos derivados de 3-((1,2,4)triazolo(4,3-a)piridin-7-il)benzamida.
EP2150544B1 (en) 2007-03-19 2016-01-13 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors
ES2329639B1 (es) 2007-04-26 2010-09-23 Laboratorios Almirall S.A. Nuevos derivados de 4,8-difenilpoliazanaftaleno.
EP2172198B1 (en) 2007-07-20 2014-04-16 Chugai Seiyaku Kabushiki Kaisha p27 PROTEIN INDUCER
JP5453290B2 (ja) 2007-11-12 2014-03-26 武田薬品工業株式会社 Ｍａｐｋ／ｅｒｋキナーゼ阻害剤
WO2009146034A2 (en) * 2008-03-31 2009-12-03 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors and methods of use thereof
EP2108641A1 (en) 2008-04-11 2009-10-14 Laboratorios Almirall, S.A. New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors
EP2113503A1 (en) 2008-04-28 2009-11-04 Laboratorios Almirall, S.A. New substituted indolin-2-one derivatives and their use as p39 mitogen-activated kinase inhibitors
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
RU2399621C2 (ru) * 2008-10-14 2010-09-20 Андрей Александрович Иващенко ЗАМЕЩЕННЫЕ 2-АЛКИЛАМИНО-3-СУЛЬФОНИЛ-ПИРАЗОЛО[1,5-a]ПИРИМИДИНЫ, АНТАГОНИСТЫ СЕРОТОНИНОВЫХ 5-HT6 РЕЦЕПТОРОВ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
RU2393157C1 (ru) * 2008-10-06 2010-06-27 Андрей Александрович Иващенко 2-АЛКИЛАМИНО-3-АРИЛСУЛЬФОНИЛ-ПИРАЗОЛО[1,5-а]ПИРИМИДИНЫ, АНТАГОНИСТЫ СЕРОТОНИНОВЫХ 5-HT6 РЕЦЕПТОРОВ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
CA2742945A1 (en) 2008-11-10 2010-05-14 Bayer Schering Pharma Aktiengesellschaft Substituted sulphonamido phenoxybenzamides
ES2548141T3 (es) 2008-11-20 2015-10-14 Glaxosmithkline Llc Compuestos químicos
EP2370568B1 (en) 2008-12-10 2017-07-19 Dana-Farber Cancer Institute, Inc. Mek mutations conferring resistance to mek inhibitors
JP2012521411A (ja) * 2009-03-26 2012-09-13 マピ ファーマ リミテッド アログリプチンの調製プロセス
CN101619063B (zh) * 2009-06-02 2011-08-10 华中师范大学 具有抗肿瘤活性的3,7,8-多取代吡啶并[4,3-d]嘧啶衍生物及制备
WO2011031308A1 (en) * 2009-09-09 2011-03-17 Cytokinetics, Incorporated Novel combinations
JP2013505939A (ja) * 2009-09-23 2013-02-21 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 組合せ
AU2010298280B2 (en) * 2009-09-23 2014-07-03 Novartis Ag Combination
JP2013505962A (ja) * 2009-09-28 2013-02-21 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 組合せ
KR20120100978A (ko) * 2009-10-08 2012-09-12 글락소스미스클라인 엘엘씨 조합물
PT2488033T (pt) 2009-10-16 2019-09-10 Novartis Ag Combinação que compreende um inibidor de mek e um inibidor de b-raf
WO2011047788A1 (en) 2009-10-21 2011-04-28 Bayer Schering Pharma Aktiengesellschaft Substituted benzosulphonamides
CN102574782B (zh) 2009-10-21 2014-10-08 拜耳知识产权有限责任公司 取代的卤代苯氧基苯甲酰胺衍生物
WO2011047795A1 (en) 2009-10-21 2011-04-28 Bayer Schering Pharma Aktiengesellschaft Substituted benzosulphonamides
ES2578191T3 (es) * 2009-11-17 2016-07-21 Novartis Ag Combinación
RU2571930C2 (ru) 2010-02-25 2015-12-27 Дана-Фарбер Кэнсер Инститьют, Инк. Мутации braf, обеспечивающие резистентность к ингибиторам braf
RU2421456C1 (ru) * 2010-02-26 2011-06-20 Общество С Ограниченной Ответственностью "Инновационная Фармацевтика" ЗАМЕЩЕННЫЕ 3-АРИЛСУЛЬФОНИЛ-ПИРАЗОЛО[1,5-a]ПИРИМИДИН-2,6-ДИАМИНЫ, АНТАГОНИСТЫ СЕРОТОНИНОВЫХ 5-НТ6 РЕЦЕПТОРОВ, СПОСОБЫ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
US20130059851A1 (en) 2010-03-09 2013-03-07 Dana-Farber Cancer Institute, Inc. Methods of Diagnosing and Treating Cancer in Patients Having or Developing Resistance to a First Cancer Therapy
US8598156B2 (en) 2010-03-25 2013-12-03 Glaxosmithkline Llc Chemical compounds
UY33288A (es) * 2010-03-25 2011-10-31 Glaxosmithkline Llc Derivados de indolina inhibidores de la proteina quinasa r del reticulo endoplasmatico
ES2689177T3 (es) * 2010-04-13 2018-11-08 Novartis Ag Combinación que comprende un inhibidor de cinasa 4 dependiente de ciclina o cinasa dependiente de ciclina (CDK4/6) y un inhibidor de mTOR para tratar cáncer
WO2011146712A1 (en) 2010-05-21 2011-11-24 Glaxosmithkline Llc Combination
UA112517C2 (uk) 2010-07-06 2016-09-26 Новартіс Аг Тетрагідропіридопіримідинові похідні
JP5903433B2 (ja) * 2010-08-26 2016-04-13 ノバルティス アーゲー 癌の治療に有用なｖｅｇｆｒ阻害剤およびｍｅｋ阻害剤の医薬的組み合わせ
CN103282351A (zh) 2010-10-29 2013-09-04 拜耳知识产权有限责任公司 取代的苯氧基吡啶
CN102020651B (zh) 2010-11-02 2012-07-18 北京赛林泰医药技术有限公司 6-芳基氨基吡啶酮甲酰胺mek抑制剂
WO2012061683A2 (en) * 2010-11-05 2012-05-10 Glaxosmithkline Llc Methods for treating cancer
US20130231346A1 (en) * 2010-11-17 2013-09-05 Glaxosmithkline Intellectual Property (No.2) Limited Methods of treating cancer
CN104689318A (zh) * 2010-11-19 2015-06-10 葛兰素史密斯克莱知识产权（第2号）有限公司 使用braf抑制剂的治疗方法
TWI505828B (zh) 2010-12-20 2015-11-01 葛蘭素史克智慧財產（第二）有限公司 新穎醫藥組成物
ES2603479T3 (es) * 2010-12-20 2017-02-27 Novartis Ag Terapia de combinación que comprende gemcitabina para el tratamiento de cáncer pancreático
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
WO2013019620A2 (en) * 2011-07-29 2013-02-07 Glaxosmithkline Llc Method of treating cancer using combination of braf inhibitor, mek inhibitor, and anti-ctla-4 antibody
BR112014002353B1 (pt) * 2011-08-01 2022-09-27 Genentech, Inc Usos de antagonistas de ligação do eixo pd-1 e inibidores de mek, composições farmacêuticas, e kit
RU2607944C2 (ru) 2011-08-31 2017-01-11 Новартис Аг Синергические композиции ингибиторов pi3k и мек
DK2790705T3 (da) 2011-12-15 2018-03-12 Novartis Ag Anvendelse af inhibitorer af aktiviteten eller funktionen af PI3K
GEP201706774B (en) 2012-03-14 2017-11-27 Lupin Ltd Heterocyclyl compounds
WO2013169858A1 (en) 2012-05-08 2013-11-14 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
CN107652289B (zh) 2012-06-13 2020-07-21 因塞特控股公司 作为fgfr抑制剂的取代的三环化合物
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
KR102134585B1 (ko) * 2012-09-04 2020-07-17 노바르티스 아게 보조 암 치료 방법
JP2016503399A (ja) * 2012-10-25 2016-02-04 ノバルティス アーゲー 組合せ
UA115250C2 (uk) 2012-11-29 2017-10-10 Новартіс Аг Фармацевтичні комбінації
US20150328320A1 (en) * 2012-11-30 2015-11-19 Glaxosmithkline Llc Novel Pharmaceutical Composition
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
EP2752191A1 (en) 2013-01-07 2014-07-09 Sanofi Compositions and methods using hdm2 antagonist and mek inhibitor
CN104902896A (zh) 2013-01-09 2015-09-09 葛兰素史密斯克莱知识产权（第2号）有限公司 组合
ES2703208T3 (es) 2013-02-27 2019-03-07 Daiichi Sankyo Co Ltd Método de predicción de la sensibilidad a un compuesto que inhibe la vía de transducción de señales de MAPK
JP6449244B2 (ja) 2013-04-19 2019-01-09 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｆｇｆｒ抑制剤としての二環式複素環
AR096433A1 (es) 2013-05-28 2015-12-30 Glaxosmithkline Intellectual Property (No 2) Ltd Método de tratamiento del cáncer y uso
WO2014195852A1 (en) 2013-06-03 2014-12-11 Glaxosmithkline Intellectual Property (No.2) Limited Combinations of an anti-pd-l1 antibody and a mek inhibitor and/or a braf inhibitor
WO2015056180A1 (en) 2013-10-15 2015-04-23 Glaxosmithkline Intellectual Property (No.2) Limited Indoline derivatives as inhibitors of perk
KR102222569B1 (ko) * 2013-10-25 2021-03-05 샹하이 헨그루이 파마수티컬 컴퍼니 리미티드 피리딘의 케톤 유도체의 제조 방법 및 제약 용도
WO2015059677A1 (en) 2013-10-26 2015-04-30 Glaxosmithkline Intellectual Property (No.2) Limited Methods of treating cancer
WO2015081566A1 (zh) * 2013-12-06 2015-06-11 杭州普晒医药科技有限公司 曲美替尼及其溶剂化物的晶型、其制备方法、含有它们的药物组合物及其用途
WO2015087279A1 (en) 2013-12-12 2015-06-18 Glaxosmithkline Intellectual Property (No.2) Limited Combinations of trametinib, panitumumab and dabrafenib for the treatment of cancer
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
EP2913048A1 (en) * 2014-02-27 2015-09-02 ratiopharm GmbH Pharmaceutical composition comprising trametinib
RS59853B1 (sr) 2014-03-14 2020-02-28 Novartis Ag Molekuli anti-lag-3 antitela i njihove upotrebe
WO2016009306A1 (en) 2014-07-15 2016-01-21 Lupin Limited Heterocyclyl compounds as mek inhibitors
CN106573060A (zh) 2014-07-15 2017-04-19 豪夫迈·罗氏有限公司 使用pd‑1轴结合拮抗剂和mek抑制剂治疗癌症的组合物
WO2016035008A1 (en) 2014-09-04 2016-03-10 Lupin Limited Pyridopyrimidine derivatives as mek inhibitors
KR20170060042A (ko) 2014-09-13 2017-05-31 노파르티스 아게 Alk 억제제의 조합 요법
CA2963281A1 (en) 2014-10-03 2016-04-07 Novartis Ag Combination therapies
WO2016055935A1 (en) 2014-10-06 2016-04-14 Glaxosmithkline Intellectual Property (No.2) Limited Combination of lysine-specific demethylase 1 inhibitor and thrombopoietin agonist
TWI716362B (zh) 2014-10-14 2021-01-21 瑞士商諾華公司 針對ｐｄ－ｌ１之抗體分子及其用途
WO2016059602A2 (en) 2014-10-16 2016-04-21 Glaxo Group Limited Methods of treating cancer and related compositions
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
EP3233918A1 (en) 2014-12-19 2017-10-25 Novartis AG Combination therapies
ES2751669T3 (es) 2015-02-20 2020-04-01 Incyte Corp Heterociclos bicíclicos como inhibidores FGFR
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
JP2016155776A (ja) * 2015-02-24 2016-09-01 学校法人兵庫医科大学 抗腫瘍効果増強剤および抗腫瘍剤
CZ2015278A3 (cs) 2015-04-24 2016-11-02 Zentiva, K.S. Krystalické formy trametinibu
EP3316902A1 (en) 2015-07-29 2018-05-09 Novartis AG Combination therapies comprising antibody molecules to tim-3
EP4378957A3 (en) 2015-07-29 2024-08-07 Novartis AG Combination therapies comprising antibody molecules to pd-1
SI3317301T1 (sl) 2015-07-29 2021-10-29 Novartis Ag Kombinirane terapije, ki obsegajo molekule protitelesa na LAG-3
WO2017037579A1 (en) 2015-08-28 2017-03-09 Novartis Ag Mdm2 inhibitors and combinations thereof
US20190365741A1 (en) 2015-08-28 2019-12-05 Novartis Ag Combinations of the cdk4/6 inhibitor lee011 and the mek1/2 inhibitor trametinib, optionally further comprising the pi3k inhibitor byl719 to treat cancer
EP3370768B9 (en) 2015-11-03 2022-03-16 Janssen Biotech, Inc. Antibodies specifically binding pd-1 and their uses
RU2605400C1 (ru) * 2015-11-13 2016-12-20 ЗАО "Р-Фарм" ПРОИЗВОДНЫЕ 1-(3-АМИНОФЕНИЛ)-6,8-ДИМЕТИЛ-5-(4-ИОД-2-ФТОР-ФЕНИЛАМИНО)-3-ЦИКЛОПРОПИЛ-1H,6H-ПИРИДО[4,3-d]ПИРИМИДИН-2,4,7-ТРИОНА В КАЧЕСТВЕ ИНГИБИТОРОВ МЕК1/2
WO2017098421A1 (en) 2015-12-08 2017-06-15 Glaxosmithkline Intellectual Property Development Limited Benzothiadiazine compounds
EP3389712B1 (en) 2015-12-17 2024-04-10 Novartis AG Antibody molecules to pd-1 and uses thereof
KR20250007056A (ko) 2016-03-04 2025-01-13 다이호야쿠힌고교 가부시키가이샤 악성 종양 치료용 제제 및 조성물
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
WO2017153952A1 (en) 2016-03-10 2017-09-14 Glaxosmithkline Intellectual Property Development Limited 5-sulfamoyl-2-hydroxybenzamide derivatives
JP7114575B2 (ja) 2016-09-19 2022-08-08 ノバルティス アーゲー Ｒａｆ阻害剤及びｅｒｋ阻害剤を含む治療用組合せ
RU2627692C1 (ru) 2016-10-10 2017-08-10 Закрытое акционерное общество "Р-Фарм" (ЗАО "Р-Фарм") N-{ 3-[3-циклопропил-5-(2-фторо-4-иодофениламино)-6,8-диметил-2,4,7-триоксо-3,4,6,7-тетрагидро-2Н-пиридо[4,3-d]пиримидин-1-ил]-фенил} -циклопропанкарбоксамида диметилсульфоксида сольват в качестве ингибитора МЕК1/2
CN107970246B (zh) * 2016-10-21 2020-08-28 中山大学 非甾体类抗炎药在提高肿瘤细胞对酪氨酸激酶抑制剂的敏感性中的应用
WO2018092064A1 (en) 2016-11-18 2018-05-24 Novartis Ag Combinations of mdm2 inhibitors and bcl-xl inhibitors
CN115025225A (zh) 2016-11-25 2022-09-09 基诺富公司 用于诱导神经干细胞的分化和保护的组合物及使用该组合物诱导神经再生的方法
KR20190090824A (ko) 2016-12-01 2019-08-02 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 암을 치료하는 방법
IL311471A (en) 2017-05-02 2024-05-01 Novartis Ag Combination therapy
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
TW201922721A (zh) 2017-09-07 2019-06-16 英商葛蘭素史克智慧財產發展有限公司 化學化合物
WO2019053617A1 (en) 2017-09-12 2019-03-21 Glaxosmithkline Intellectual Property Development Limited CHEMICAL COMPOUNDS
WO2019099838A1 (en) 2017-11-16 2019-05-23 Novartis Ag Combination therapies
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
SG11202008435SA (en) 2018-03-19 2020-10-29 Taiho Pharmaceutical Co Ltd Pharmaceutical composition including sodium alkyl sulfate
WO2019180141A1 (en) 2018-03-23 2019-09-26 Bayer Aktiengesellschaft Combinations of rogaratinib
CA3094780A1 (en) 2018-03-30 2019-10-03 Novartis Ag A triple pharmaceutical combination comprising dabrafenib, trametinib and an erk inhibitor
EP3560516A1 (en) 2018-04-27 2019-10-30 Bergen Teknologioverforing AS Combination therapy including beta-sitosterol in combination with at least one of a braf inhibitor, a mek inhibitor or an erk inhibitor and methods and use thereof
PE20210919A1 (es) 2018-05-04 2021-05-19 Incyte Corp Sales de un inhibidor de fgfr
CN119241541A (zh) 2018-05-04 2025-01-03 因赛特公司 Fgfr抑制剂的固体形式和其制备方法
AU2019274657A1 (en) 2018-05-24 2020-12-10 Janssen Biotech, Inc. PSMA binding agents and uses thereof
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
JP2022504905A (ja) 2018-10-16 2022-01-13 ノバルティス アーゲー 標的化療法に対する応答を予測するためのバイオマーカーとしての単独の又は免疫マーカーと組み合わせた腫瘍突然変異負荷
CN109320513B (zh) * 2018-11-09 2021-03-16 安庆奇创药业有限公司 一种合成曲美替尼的方法
JP7393808B2 (ja) * 2018-11-20 2023-12-07 エヌフレクション セラピューティクス インコーポレイテッド 皮膚障害の処置のためのナフチリジノン－アニリン化合物
WO2020106306A1 (en) 2018-11-20 2020-05-28 Nflection Therapeutics, Inc. Cyanoaryl-aniline compounds for treatment of dermal disorders
CN113498340A (zh) 2018-11-20 2021-10-12 恩福莱克逊治疗有限公司 用于治疗皮肤疾病噻吩基苯胺化合物
IL283487B2 (en) 2018-11-30 2024-07-01 Glaxosmithkline Ip Dev Ltd Compounds useful in hiv therapy
CN113271945A (zh) 2018-12-20 2021-08-17 诺华股份有限公司 包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案和药物组合
WO2020161654A1 (en) * 2019-02-06 2020-08-13 Aurobindo Pharma Limited A process for the preparation of trametinib acetic acid solvate
MX2021009763A (es) 2019-02-15 2021-09-08 Novartis Ag Derivados de 3-(1-oxo-5-(piperidin-4-il)isoindolin-2-il)piperidina -2,6-diona y usos de los mismos.
MX2021009764A (es) 2019-02-15 2021-09-08 Novartis Ag Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona sustituidos y usos de los mismos.
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
AR118720A1 (es) 2019-04-19 2021-10-27 Janssen Biotech Inc Métodos para tratar el cáncer de próstata con un anticuerpo anti-psma / cd3
EP4563150A3 (en) 2019-05-13 2025-07-23 Novartis AG New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl) isonicotinamide as raf inhibitors for the treatment of cancer
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021018112A1 (zh) * 2019-07-29 2021-02-04 江苏恒瑞医药股份有限公司 一种1，6-二氢吡啶-3-甲酰胺衍生物的制备方法
WO2021018941A1 (en) 2019-07-31 2021-02-04 Glaxosmithkline Intellectual Property Development Limited Methods of treating cancer
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
GEP20247679B (en) 2019-10-14 2024-10-10 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
IL293001A (en) 2019-12-04 2022-07-01 Incyte Corp Derivatives of fgfr repressors
CA3163875A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
JP2023507190A (ja) 2019-12-20 2023-02-21 ノバルティス アーゲー 増殖性疾患を治療するための抗ＴＧＦβ抗体及びチェックポイント阻害薬の使用
EP4087868A4 (en) * 2020-01-08 2024-03-20 Icahn School of Medicine at Mount Sinai SMALL MOLECULAR MODULATORS FOR KSR-BONDED MEK
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
EP4106756A1 (en) 2020-02-18 2022-12-28 Novartis AG Therapeutic combinations comprising a raf inhibitor for use in treating braf mutant nsclc
EP4134081A4 (en) 2020-04-10 2024-05-01 Taiho Pharmaceutical Co., Ltd. Cancer therapy using 3,5-disubstituted benzene alkynyl compound and mek inhibitor
WO2021209563A1 (en) 2020-04-16 2021-10-21 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
JP2023525100A (ja) 2020-05-12 2023-06-14 ノバルティス アーゲー Ｃｒａｆ阻害剤を含む治療的組み合わせ
AU2021285032A1 (en) * 2020-06-02 2022-12-08 Boehringer Ingelheim International Gmbh Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
EP4168007A1 (en) 2020-06-23 2023-04-26 Novartis AG Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
US20230321110A1 (en) 2020-08-31 2023-10-12 Novartis Ag Combination therapy of a raf inhibitor and a mek inhibitor for the treatment of sarcoma
WO2022120353A1 (en) 2020-12-02 2022-06-09 Ikena Oncology, Inc. Tead inhibitors and uses thereof
AU2021392040A1 (en) 2020-12-02 2023-06-29 Ikena Oncology, Inc. Tead inhibitors and uses thereof
WO2022159986A1 (en) 2021-01-25 2022-07-28 Ikena Oncology, Inc. Combination of a 3-(imidazol-4-yl)-4-(amino)-benzenesulfonamide tead inhibitor with an egfr inhibitor and/or mek inhibitor for use in the treatment of lung cancer
MX2023008909A (es) 2021-01-28 2023-10-23 Janssen Biotech Inc Proteínas de unión a psma y usos de estas.
EP4288434A1 (en) 2021-02-02 2023-12-13 Les Laboratoires Servier Selective bcl-xl protac compounds and methods of use
CN117321418A (zh) 2021-03-18 2023-12-29 诺华股份有限公司 癌症生物标志物及其使用方法
TWI825637B (zh) 2021-03-31 2023-12-11 美商輝瑞股份有限公司 啶－１，６（２ｈ，７ｈ）－二酮
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
CN117479942A (zh) 2021-04-09 2024-01-30 勃林格殷格翰国际有限公司 抗癌疗法
JP2024513575A (ja) 2021-04-12 2024-03-26 インサイト・コーポレイション Ｆｇｆｒ阻害剤及びネクチン－４標的化剤を含む併用療法
IL307673A (en) * 2021-04-16 2023-12-01 Ikena Oncology Inc MEK inhibitors and their use
JP2024517788A (ja) 2021-05-05 2024-04-23 ノバルティス アーゲー Ｍｐｎｓｔの処置のための化合物及び組成物
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación
TW202313041A (zh) 2021-06-09 2023-04-01 瑞士商諾華公司 包含達拉菲尼、曲美替尼和shp2抑制劑之三重藥物組合
WO2022261160A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
AR126101A1 (es) 2021-06-09 2023-09-13 Incyte Corp Heterociclos tricíclicos como inhibidores de fgfr
WO2023114984A1 (en) 2021-12-17 2023-06-22 Ikena Oncology, Inc. Tead inhibitors and uses thereof
EP4486920A2 (en) 2022-03-02 2025-01-08 Novartis AG Precision therapy for the treatment of cancer
CN114456166B (zh) * 2022-03-30 2023-06-16 沈阳药科大学 5-取代氨基-3-甲基吡啶并[2,3-d]嘧啶类化合物及其制备与应用
CN114573581B (zh) * 2022-03-30 2023-09-01 沈阳药科大学 5-取代氨基-1,3-二取代苯基吡啶并[2,3-d]嘧啶类化合物及其制备与应用
CN114605408B (zh) * 2022-03-30 2023-06-16 沈阳药科大学 5-羟基-1,3-二取代苯基吡啶并[2,3-d]嘧啶类化合物及其制法和应用
CN114573582B (zh) * 2022-03-30 2023-06-16 沈阳药科大学 1,2,3,4-四氢吡啶并[2,3-d]嘧啶类化合物及其制备方法和应用
CA3256012A1 (en) 2022-05-20 2023-11-23 Les Laboratoires Servier ANTIBODY-DRUG CONJUGATES, MET INHIBITORS BCL-XL, AND THEIR METHODS OF USE
KR20250027281A (ko) 2022-05-20 2025-02-25 노파르티스 아게 Epha2 bcl-xl 억제제 항체-약물 접합체 및 그의 사용 방법
CN114853754B (zh) 2022-05-23 2023-04-18 云白药征武科技(上海)有限公司 一种硫代酰胺衍生物及其制备方法和应用
KR20250040894A (ko) 2022-05-25 2025-03-25 이케나 온콜로지, 인코포레이티드 Mek 억제제 및 이의 용도
AR129423A1 (es) 2022-05-27 2024-08-21 Viiv Healthcare Co Compuestos útiles en la terapia contra el hiv
EP4676540A1 (en) 2023-03-10 2026-01-14 Novartis AG Panras inhibitor antibody-drug conjugates and methods of use thereof
TW202540185A (zh) 2023-11-22 2025-10-16 法商施維雅藥廠 抗cd74抗體藥物結合物及其使用方法
WO2025132408A2 (en) 2023-12-21 2025-06-26 Synthon B.V. Solvates of trametinib
WO2025132190A1 (en) 2023-12-22 2025-06-26 Synthon B.V. A process for making trametinib
WO2025146444A1 (en) 2024-01-03 2025-07-10 Bayer Aktiengesellschaft Darolutamide in combination with braf and mek inhibitors for melanoma treatment
CN120441478A (zh) * 2024-02-07 2025-08-08 成都赜灵生物医药科技有限公司 一种六元内酰胺类化合物及其应用
WO2025215536A1 (en) 2024-04-10 2025-10-16 Novartis Ag Macrocyclic panras inhibitors for the treatment of cancer
CN118121604B (zh) * 2024-05-07 2024-06-25 四川成都中农大现代农业产业研究院 表没食子儿茶素没食子酸酯的组合物及其作为铜离子载体抗肝癌增敏剂的用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3139432A (en) * 1963-06-24 1964-06-30 Mead Johnson & Co Pyrido [2, 3-d] pyrimidine-2, 4, 5, 7-tetraones
DE4035479A1 (de) * 1990-11-08 1992-05-14 Basf Ag Substituierte pyrido (2,3-d)pyrimidin-2,4(1h,3h)-dione
KR20010101203A (ko) 1998-12-15 2001-11-14 로즈 암스트롱, 크리스틴 에이. 트러트웨인 Ｍｅｋ 저해제의 이식 조직 거부를 예방하기 위한 용도
CA2346448A1 (en) 1998-12-16 2000-06-22 Warner-Lambert Company Treatment of arthritis with mek inhibitors
JP2002534381A (ja) 1999-01-07 2002-10-15 ワーナー−ランバート・カンパニー Ｍｅｋ阻害剤を用いた抗ウィルス法
BR9916785A (pt) 1999-01-07 2001-10-23 Warner Lambert Co Tratamento de asma com inibidores mek
DE60005688T2 (de) 1999-07-16 2004-04-29 Warner-Lambert Co. Llc Verfahren zur behandlung von chronischem schmerz durch verabreichung von einem mek hemmer
UA72612C2 (en) * 2000-07-06 2005-03-15 Pyrido[2.3-d]pyrimidine and pyrimido[4.5-d]pyrimidine nucleoside analogues, prodrugs and method for inhibiting growth of neoplastic cells
CN1219753C (zh) 2000-07-19 2005-09-21 沃尼尔·朗伯公司 4－碘苯氨基苯氧肟酸的氧合酯
WO2002006520A1 (en) 2000-07-19 2002-01-24 Chugai Seiyaku Kabushiki Kaisha Method of screening compound controlling mek/erk signal transduction and medicinal use of the compound
WO2002087620A1 (en) 2001-04-27 2002-11-07 Chugai Seiyaku Kabushiki Kaisha Chondrogenesis promoters
IL149462A0 (en) 2001-05-09 2002-11-10 Warner Lambert Co Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor
US6825180B2 (en) * 2001-05-18 2004-11-30 Cell Therapeutics, Inc. Pyridopyrimidine compounds and their uses
GEP20063909B (en) * 2002-01-22 2006-08-25 Warner Lambert Co 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d] PYRIMIDIN-7-ONES

Also Published As

Publication number Publication date
RS50569B (sr) 2010-05-07
MXPA06014478A (es) 2007-03-21
CN101912400B (zh) 2013-06-26
BRPI0511967B1 (pt) 2019-05-07
KR20070034581A (ko) 2007-03-28
SI2298768T1 (en) 2013-01-31
JP2008201788A (ja) 2008-09-04
CY1113538T1 (el) 2016-06-22
CN101006086A (zh) 2007-07-25
BRPI0511967B8 (pt) 2021-05-25
CY1107253T1 (el) 2012-11-21
NO2016021I2 (no) 2016-11-24
NL300701I1 (da) 2015-12-29
PT1761528E (pt) 2008-04-15
HRP20080018T3 (en) 2008-01-31
NO338355B1 (no) 2016-08-08
DK1761528T3 (da) 2008-05-05
EP1761528B1 (en) 2008-01-09
CN101912400A (zh) 2010-12-15
ATE383360T1 (de) 2008-01-15
RS52670B (sr) 2013-06-28
FR14C0083I2 (fr) 2015-02-20
FR14C0083I1 (fr) 2015-02-01
EP1761528A1 (en) 2007-03-14
ME01480B (me) 2014-04-20
EP1894932A1 (en) 2008-03-05
IL179671A0 (en) 2007-05-15
PT2298768E (pt) 2012-12-05
NO2016021I1 (no) 2016-11-24
EP2298768B9 (en) 2013-04-24
CA2569850A1 (en) 2005-12-22
ES2297723T3 (es) 2008-05-01
JP2012072155A (ja) 2012-04-12
CA2569850C (en) 2011-04-05
NZ552090A (en) 2009-06-26
SI1761528T1 (sl) 2008-06-30
DK2298768T3 (da) 2013-01-02
CN101006086B (zh) 2010-09-29
JP2008501631A (ja) 2008-01-24
ES2397825T3 (es) 2013-03-11
JP5421974B2 (ja) 2014-02-19
JP4913768B2 (ja) 2012-04-11
HRP20121020T1 (hr) 2013-01-31
JP4163738B2 (ja) 2008-10-08
RU2007101158A (ru) 2008-07-20
HK1107084A1 (en) 2008-03-28
EP2298768A1 (en) 2011-03-23
NL300701I2 (da) 2015-12-29
RU2364596C2 (ru) 2009-08-20
BRPI0511967A (pt) 2008-01-22
NO20070155L (no) 2007-02-13
CA2727841A1 (en) 2005-12-22
CY2014045I2 (el) 2019-07-10
DE602005004286D1 (de) 2008-02-21
DE602005004286T2 (de) 2009-01-02
AU2005252110A1 (en) 2005-12-22
EP2298768B1 (en) 2012-11-14
CY2014045I1 (el) 2019-07-10
KR100883289B1 (ko) 2009-02-11
PL2298768T3 (pl) 2013-03-29
WO2005121142A1 (en) 2005-12-22
AU2005252110B2 (en) 2008-09-04
PL1761528T3 (pl) 2008-05-30

Similar Documents

Publication Publication Date Title
LU92602I2 (fr) Trametinib, optionnellement sous la forme d'un sel, hydrate ou solvate pharmaceutiquement acceptablede celui-ci
MX2009009590A (es) Aminopirimidinas utiles como inhibidores de proteinas cinasas.
SG166827A1 (en) Aminopyrimidines useful as kinase inhibitors
IL200793A0 (en) Aminopyrimidines, compositions comprising the same and use thereof for inhibiting protein kinases
LU92155I2 (fr) Crizotinib, éventuellement sous la forme d'un sel,hydrate ou solvate pharmeceutiquement acceptable
SG170828A1 (en) Deazapurines useful as inhibitors of janus kinases
MX2009006700A (es) Derivados de 5-ciano-4-(pirolo)[2,3b]piridina-3-il)-pirimidinas utiles como inhibidores de proteina-cinasas.
MX2007014619A (es) Pirrolopiridinas de utilidad como inhibidores de proteina quinasa.
MX2009010037A (es) Aminopirimidinas utiles como inhibidores de cinasas.
MX2009006742A (es) Inhibidores acilaminopirazoles como fgfr.
MX2010006799A (es) Benzofuropirimidinonas como inhibidores de la proteina cinasa.
TW200613306A (en) Imidazotriazines as protein kinase inhibitors
MX2009006345A (es) Compuestos utiles como inhibidores de proteina cinasa.
ATE457988T1 (de) A2a-adenosin-rezeptor-antagonisten
MX2009011811A (es) Aminopirimidinas utiles como inhibidores de cinasa.
DE602004011394D1 (en) Thiazolderivate
MX2009010127A (es) Compuestos utiles como inhibidores de janus cinasas.
MX2009011059A (es) Aminopirimidinas utiles como inhibidores de cinasas.
MX2010001020A (es) Derivados de pirimidina utiles para el tratamiento de condiciones inflamatorias o alergicas.
MY154591A (en) Therapeutic compositions comprising a specific endothelin receptor antagonist and a pde5 inhibitor
MX2007013624A (es) Inhibidores de proteina cinasa.
IL195016A0 (en) 1h-indol-5-yl-piperazin-1-yl-methanone derivatives
WO2007024843A3 (en) Pyrimidinyl-pyrazole inhibitors of aurora kinases
MXPA05012772A (es) Derivados de benzotiazol y uso de los mismos en el tratamiento de enfermedades relacionadas con el receptor a2a de adenosina.
TNSN08093A1 (en) Quinoline derivatives and use as antitumor agents